Advanced search
1 file | 322.15 KB

Altered serum N-glycomics in chronic hepatitis B patients

(2010) LIVER INTERNATIONAL. 30(2). p.259-267
Author
Organization
Abstract
Background: We previously reported on serum N-glycans as markers for the diagnosis of cirrhosis in patients with chronic hepatitis C infection. Our present study aimed to evaluate the use of serum glycan markers for the diagnosis of liver fibrosis in patients with chronic hepatitis B infection. Methods: Patients with hepatitis B virus (HBV) infection (n = 173) were diagnosed by clinical laboratory analysis and histological examination. Liver fibrosis was staged using Ishak score. N-glycan profiles of serum proteins were determined by DNA sequencer-based carbohydrate analytical profiling. Results: We found that in HBV patients, like in hepatitis C virus patients, several serum N-glycans were altered during the development of liver fibrosis. We found higher levels of total agalactosylated biantennary glycans in fibrosis patients with HBV infection than in healthy controls. The biantennary (NA2) and the triantennary (NA3) N-glycans decreased significantly (Po0.001) with increased severity of fibrosis. The diagnostic power of serum glycan marker (GlycoFibroTest) [area under the curve (AUC) = 0.735) was similar to that of FibroTest (AUC= 0.740) for discriminating between moderate and advanced fibrosis (F3–F6) from non- or mild fibrosis (F0–F2). However, GlycoFibroTest (AUC= 0.740) was slightly better than FibroTest (AUC = 0.696) for distinguishing fibrotic patients (F1 or more) from nonfibrotic patients (F0). Conclusions: The assay for serum glycan profiling showed satisfactory reproducibility and is a non-invasive blood test for the diagnosis of liver fibrosis. The changes of N-glycan level in serum can be used to monitor or follow-up the progress of fibrosis using specific N-glycan markers.
Keywords
BIOPSY, GLYCOSYLATION, DIAGNOSIS, non-invasive, N-glycan, liver fibrosis, HBV, glycomics, cirrhosis, CIRRHOSIS, AGALACTOSYL IGG, PREDICTIVE MODEL, PROTEIN GLYCOMICS, TRANSIENT ELASTOGRAPHY, LIVER FIBROSIS, HEPATOCELLULAR-CARCINOMA

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 322.15 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Gui, Hong-Lian, Chung-Fang Gao, Hui Wang, Xue-En Liu, Qing Xie, Sylviane Dewaele, Ling Wang, et al. 2010. “Altered Serum N-glycomics in Chronic Hepatitis B Patients.” Liver International 30 (2): 259–267.
APA
Gui, H.-L., Gao, C.-F., Wang, H., Liu, X.-E., Xie, Q., Dewaele, S., Wang, L., et al. (2010). Altered serum N-glycomics in chronic hepatitis B patients. LIVER INTERNATIONAL, 30(2), 259–267.
Vancouver
1.
Gui H-L, Gao C-F, Wang H, Liu X-E, Xie Q, Dewaele S, et al. Altered serum N-glycomics in chronic hepatitis B patients. LIVER INTERNATIONAL. 2010;30(2):259–67.
MLA
Gui, Hong-Lian, Chung-Fang Gao, Hui Wang, et al. “Altered Serum N-glycomics in Chronic Hepatitis B Patients.” LIVER INTERNATIONAL 30.2 (2010): 259–267. Print.
@article{822827,
  abstract     = {Background: We previously reported on serum N-glycans as markers for the diagnosis of cirrhosis in patients with chronic hepatitis C infection. Our present study aimed to evaluate the use of serum glycan markers for the diagnosis of liver fibrosis in patients with chronic hepatitis B infection. 
Methods: Patients with hepatitis B virus (HBV) infection (n = 173) were diagnosed by clinical laboratory analysis and histological examination. Liver fibrosis was staged using Ishak score. N-glycan profiles of serum proteins were determined by DNA sequencer-based carbohydrate analytical profiling. 
Results: We found that in HBV patients, like in hepatitis C virus patients, several serum N-glycans were altered during the development of liver fibrosis. We found higher levels of total agalactosylated biantennary glycans in fibrosis patients with HBV infection than in healthy controls. The biantennary (NA2) and the triantennary (NA3) N-glycans decreased significantly (Po0.001) with increased severity of fibrosis. The diagnostic power of serum glycan marker (GlycoFibroTest) [area under the curve (AUC) = 0.735) was similar to that of FibroTest (AUC= 0.740) for discriminating between moderate and advanced fibrosis (F3--F6) from non- or mild fibrosis (F0--F2). However, GlycoFibroTest (AUC= 0.740) was slightly better than FibroTest (AUC = 0.696) for distinguishing fibrotic patients (F1 or more) from nonfibrotic patients (F0). 
Conclusions: The assay for serum glycan profiling showed satisfactory reproducibility and is a non-invasive blood test for the diagnosis of liver fibrosis. The changes of N-glycan level in serum can be used to monitor or follow-up the progress of fibrosis using specific N-glycan markers.},
  author       = {Gui, Hong-Lian and Gao, Chung-Fang and Wang, Hui and Liu, Xue-En and Xie, Qing and Dewaele, Sylviane and Wang, Ling and Zhuang, Hui and Contreras, Roland and Libert, Claude and Chen, Cuiying},
  issn         = {1478-3223},
  journal      = {LIVER INTERNATIONAL},
  language     = {eng},
  number       = {2},
  pages        = {259--267},
  title        = {Altered serum N-glycomics in chronic hepatitis B patients},
  url          = {http://dx.doi.org/10.1111/j.1478-3231.2009.02170.x},
  volume       = {30},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: